Legend Biotech
Legend Biotech
LEGN
NASDAQ
38.68
USD
-3.03%
About
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM).
In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer.
It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 433.3K |
| Three Month Average Volume | 21.5M |
| High Low | |
| Fifty-Two Week High | 72.38 USD |
| Fifty-Two Week Low | 38.6 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 03 Jun 2024 |
| Price and Volume | |
| Current Price | 57.55 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -0.38% |
| Thirteen Week Relative Price Change | 34.39% |
| Twenty-Six Week Relative Price Change | -20.13% |
| Fifty-Two Week Relative Price Change | -33.78% |
| Year-to-Date Relative Price Change | -19.23% |
| Price Change | |
| One Day Price Change | 1.48% |
| Thirteen Week Price Change | 43.84% |
| Twenty-Six Week Price Change | -12.18% |
| Five Day Price Change | 0.09% |
| Fifty-Two Week Price Change | -17.03% |
| Year-to-Date Price Change | -4.35% |
| Month-to-Date Price Change | 2.06% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 6.87903 USD |
| Book Value Per Share (Most Recent Quarter) | 6.32744 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 6.8567 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 6.31231 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.93286 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.61937 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.50532 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.94324 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.567 USD |
| Normalized (Last Fiscal Year) | -2.94324 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.94324 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.567 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.94324 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.567 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 7.19623 USD |
| Cash Per Share (Most Recent Quarter) | 7.055 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.8271 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.44719 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.90441 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -211 |
| Cash Flow Revenue (Trailing Twelve Months) | -36 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -62.95% |
| Pretax Margin (Last Fiscal Year) | -182.41% |
| Pretax Margin (5 Year) | -298.48% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 49.42% |
| Gross Margin (Trailing Twelve Months) | 60.28% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -185.16% |
| Operating Margin (Trailing Twelve Months) | -81.89% |
| Operating Margin (5 Year) | -298.62% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -181.75% |
| Net Profit Margin (Trailing Twelve Months) | -62.50% |
| Net Profit Margin (5 Year) | -286.51% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 152.62% |
| Tangible Book Value (5 Year) | 170.58% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 154.36% |
| Revenue Growth (3 Year) | 42.15% |
| Revenue Change (Trailing Twelve Months) | 176.93% |
| Revenue Per Share Growth | 33.64% |
| Revenue Growth (5 Year) | 56.08% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 1.57% |
| Total Debt (5 Year) | 137.86% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 91.23% |
| EPS Change (Trailing Twelve Months) | 50.48% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 9 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -953,344,000 |
| Net Debt (Last Fiscal Year) | -980,402,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 37 |
| Price to Sales (Trailing Twelve Months) | 23 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 8 |
| Price to Book (Most Recent Quarter) | 9 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 26 |
| Long Term Debt to Equity (Most Recent Quarter) | 29 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 7 |
| Quick Ratio (Most Recent Quarter) | 5 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -415,998,000 |
| Free Cash Flow (Trailing Twelve Months) | -164,610,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -28 |
| Net Interest Coverage (Trailing Twelve Months) | -17 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 26 |
| Total Debt to Equity (Most Recent Quarter) | 29 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -32.60% |
| Return on Assets (Trailing Twelve Months) | -15.29% |
| Return on Assets (5 Year) | -37.71% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -51.94% |
| Return on Equity (Trailing Twelve Months) | -22.21% |
| Return on Equity (5 Year) | -60.09% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -38.89% |
| Return on Investment (Trailing Twelve Months) | -17.63% |
| Return on Investment (5 Year) | -47.19% |